Regenerx Biopharmaceuticals Inc (RGRX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
15245 SHADY GROVE ROAD ROCKVILLE, MD 20850 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 291 | 1,232 | 428 | 640 | 237 | 182 | |||
| Cash and cash equivalent | 291 | 1,232 | 428 | 640 | 237 | 182 | |||
| Prepaid expense | 16 | 20 | 50 | 42 | 37 | 35 | |||
| Other undisclosed current assets | |||||||||
| Total current assets: | 307 | 1,252 | 478 | 682 | 274 | 217 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 70 | 28 | 68 | 24 | ✕ | ✕ | |||
| Property, plant and equipment | (99) | 1 | 4 | ||||||
| Other noncurrent assets | 6 | 6 | 6 | 6 | 6 | 6 | |||
| Other undisclosed noncurrent assets | 99 | ||||||||
| Total noncurrent assets: | 75 | 33 | 74 | 30 | 7 | 10 | |||
| TOTAL ASSETS: | 382 | 1,285 | 552 | 712 | 281 | 227 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 434 | 325 | 248 | 139 | 183 | 299 | |||
| Accounts payable | 64 | 64 | 39 | 44 | 92 | 66 | |||
| Accrued liabilities | 370 | 262 | 209 | 95 | 91 | 232 | |||
| Deferred revenue | 77 | 77 | 77 | 77 | ✕ | ✕ | |||
| Debt | 34 | 27 | 55 | 591 | |||||
| Derivative instruments and hedges, liabilities | 1,184 | ||||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 79 | ||
| Other undisclosed current liabilities | 43 | 28 | 41 | 77 | |||||
| Total current liabilities: | 554 | 430 | 400 | 242 | 315 | 2,153 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 49 | 708 | 44 | ||||||
| Long-term debt, excluding current maturities | 22 | 708 | 44 | ||||||
| Liabilities, other than long-term debt | 1,901 | 1,948 | 2,025 | 2,101 | 2,146 | ||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 2,046 | ||
| Deferred revenue | 1,871 | 1,948 | 2,025 | 2,101 | ✕ | ✕ | |||
| Operating lease, liability | 30 | 28 | ✕ | ✕ | |||||
| Derivative instruments and hedges, liabilities | 101 | ||||||||
| Other undisclosed noncurrent liabilities | 1,373 | 1,137 | 902 | 2,178 | |||||
| Total noncurrent liabilities: | 3,274 | 3,085 | 2,976 | 2,809 | 2,178 | 2,190 | |||
| Total liabilities: | 3,828 | 3,515 | 3,376 | 3,052 | 2,493 | 4,343 | |||
| Equity | |||||||||
| Equity, attributable to parent | (3,445) | (2,230) | (2,824) | (2,340) | (2,212) | (4,116) | |||
| Common stock | 144 | 144 | 133 | 132 | 128 | 110 | |||
| Additional paid in capital | 108,628 | 108,116 | 105,935 | 104,897 | 103,541 | 100,333 | |||
| Accumulated deficit | (112,217) | (110,490) | (108,892) | (107,369) | (105,882) | (104,559) | |||
| Total equity: | (3,445) | (2,230) | (2,824) | (2,340) | (2,212) | (4,116) | |||
| TOTAL LIABILITIES AND EQUITY: | 382 | 1,285 | 552 | 712 | 281 | 227 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 77 | 77 | 77 | 77 | 70 | 57 | ||
| Gross profit: | 77 | 77 | 77 | 77 | 70 | 57 | ||
| Operating expenses | (1,479) | (1,405) | (1,371) | (1,339) | (1,393) | (1,501) | ||
| Operating loss: | (1,402) | (1,329) | (1,295) | (1,262) | (1,323) | (1,445) | ||
| Nonoperating income (expense) | (325) | (269) | (229) | (142) | (670) | 1,830 | ||
| Other nonoperating expense | (583) | |||||||
| Interest and debt expense | (326) | (325) | (233) | (153) | (87) | (171) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (2,053) | (1,923) | (1,756) | (1,558) | (2,081) | 214 | ||
| Other undisclosed income from continuing operations before income taxes | 326 | 325 | 233 | 153 | 87 | 171 | ||
| Income (loss) from continuing operations before income taxes: | (1,727) | (1,598) | (1,523) | (1,404) | (1,994) | 385 | ||
| Income tax expense (benefit) | 312 | 265 | 355 | 213 | 452 | (99) | ||
| Other undisclosed income from continuing operations | ||||||||
| Income (loss) from continuing operations: | (1,415) | (1,333) | (1,168) | (1,191) | (1,542) | 286 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | (1,333) | (1,168) | (1,191) | (1,542) | 286 | ||
| Net income (loss): | (1,415) | (1,333) | (1,168) | (1,191) | (1,542) | 286 | ||
| Other undisclosed net loss attributable to parent | (312) | (265) | (355) | (213) | (452) | |||
| Net income (loss) attributable to parent: | (1,727) | (1,598) | (1,523) | (1,404) | (1,994) | 286 | ||
| Other undisclosed net loss available to common stockholders, basic | (83) | |||||||
| Net income (loss) available to common stockholders, diluted: | (1,727) | (1,598) | (1,523) | (1,487) | (1,994) | 286 | ||
Comprehensive Income ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (1,415) | (1,333) | (1,168) | (1,191) | (1,542) | 286 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (1,415) | (1,333) | (1,168) | (1,191) | (1,542) | 286 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.